

## DAFTAR PUSTAKA

- Amir Nurmiati. (2021). *Buku Ajar Psikiatri-FKUI* (H. G. Elvira D.S., Ed.; Edisi Ketiga). Badan Penerbit FKUI.
- Allott, K., Chopra, S., Rogers, J., Dauvermann, M. R., & Clark, S. R. (2024). Advancing understanding of the mechanisms of antipsychotic-associated cognitive impairment to minimise harm: a call to action. *Molecular Psychiatry*. <https://doi.org/10.1038/s41380-024-02503-x>
- Aricioglu, F., Ozkartal, C. S., Unal, G., Dursun, S., Cetin, M., & Müller, N. (2016). Neuroinflammation in Schizophrenia: A Critical Review and The Future. *Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology*, 26(4), 429–437. <https://doi.org/10.5455/bcp.20161123044657>
- Azmanova, M., Pitto-Barry, A., & Barry, N. P. E. (2018). Schizophrenia: synthetic strategies and recent advances in drug design. *MedChemComm*, 9(5), 759–782. <https://doi.org/10.1039/C7MD00448F>
- Baek, S. H., Kim, H., Kim, J. W., Ryu, S., Lee, J. Y., Kim, J. M., Shin, I. S., & Kim, S. W. (2022). Association between Peripheral Inflammatory Cytokines and Cognitive Function in Patients with First-Episode Schizophrenia. *Journal of Personalized Medicine*, 12(7). <https://doi.org/10.3390/jpm12071137>
- Barlatti, S., Deste, G., De Peri, L., Ariu, C., & Vita, A. (2013). Cognitive Remediation in Schizophrenia: Current Status and Future Perspectives. *Schizophrenia Research and Treatment*, 2013, 1–12. <https://doi.org/10.1155/2013/156084>
- Białoń, M., & Wąsik, A. (2022). Advantages and Limitations of Animal Schizophrenia Models. *International Journal of Molecular Sciences*, 23(11), 5968. <https://doi.org/10.3390/ijms23115968>
- Bishop, J. R., Zhang, L., & Lizano, P. (2022). Inflammation Subtypes and Translating Inflammation-Related Genetic Findings in Schizophrenia and Related Psychoses: A Perspective on Pathways for Treatment Stratification and Novel Therapies. *Harvard Review of Psychiatry*, 30(1), 59–70. <https://doi.org/10.1097/HRP.0000000000000321>
- Bowie, C. R., Bell, M. D., Fiszdon, J. M., Johannesen, J. K., Lindenmayer, J. P., McGurk, S. R., Medalia, A. A., Penadés, R., Saperstein, A. M., Twamley, E. W., Ueland, T., & Wykes, T. (2020). Cognitive

- remediation for schizophrenia: An expert working group white paper on core techniques. In *Schizophrenia Research* (Vol. 215, pp. 49–53). Elsevier B.V. <https://doi.org/10.1016/j.schres.2019.10.047>
- Caruso, G., Grasso, M., Fidilio, A., Tascetta, F., Drago, F., & Caraci, F. (2020). Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia. *Pharmaceuticals*, 13(12), 457. <https://doi.org/10.3390/ph13120457>
- Cella, M., Reeder, C., & Wykes, T. (2015). Cognitive remediation in schizophrenia—now it is really getting personal. *Current Opinion in Behavioral Sciences*, 4, 147–151. <https://doi.org/10.1016/j.cobeha.2015.05.005>
- Cha, H. Y., & Yang, S. J. (2020). Anti-Inflammatory Diets and Schizophrenia. *Clinical Nutrition Research*, 9(4), 241. <https://doi.org/10.7762/cnr.2020.9.4.241>
- Chien, W. T., & Yip, A. L. K. (2013). Current approaches to treatments for schizophrenia spectrum disorders, part I: An overview and medical treatments. In *Neuropsychiatric Disease and Treatment* (Vol. 9, pp. 1311–1332). Dove Medical Press Ltd. <https://doi.org/10.2147/NDT.S37485>
- Dawidowski, B., Górniak, A., Podwalski, P., Lebiecka, Z., Misiak, B., & Samochoń, J. (2021). The Role of Cytokines in the Pathogenesis of Schizophrenia. *Journal of Clinical Medicine*, 10(17), 3849. <https://doi.org/10.3390/jcm10173849>
- de Bartolomeis, A., Barone, A., Vellucci, L., Mazza, B., Austin, M. C., Iasevoli, F., & Ciccarelli, M. (2022). Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review. *Molecular Neurobiology*, 59(10), 6460–6501. <https://doi.org/10.1007/s12035-022-02976-3>
- Departemen Kesehatan Republik Indonesia. (2018). Katalog Data - Layanan Permintaan Data \_ Kementerian Kesehatan RI. *Riskesdas*.
- Effendy, E., Amin, M. M., & Utami, N. (2021). Role of Tumor Necrosis Factor-Alpha in Schizophrenia and Cognitive Impairment. *Open Access Macedonian Journal of Medical Sciences*, 9(T3), 160–163. <https://doi.org/10.3889/oamjms.2021.6289>
- Eka Putri Widyarti, Sherly Limantara, & Husnul Khatimah. (2019). Gambaran Faktor Prognosis pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum. *Homeostatis*, 2, 509–518.

- Fisher, M., Loewy, R., Hardy, K., Schlosser, D., & Vinogradov, S. (2013). Cognitive Interventions Targeting Brain Plasticity in the Prodromal and Early Phases of Schizophrenia. *Annual Review of Clinical Psychology*, 9(1), 435–463. <https://doi.org/10.1146/annurev-clinpsy-032511-143134>
- Guo, J. Y., Ragland, J. D., & Carter, C. S. (2019). Memory and cognition in schizophrenia. In *Molecular Psychiatry* (Vol. 24, Issue 5, pp. 633–642). Nature Publishing Group. <https://doi.org/10.1038/s41380-018-0231-1>
- Guzman, F. (2015). *Antipsychotics: The Essentials Module 2: Mechanism of Action of First and Second Generation Antipsychotics*.
- Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., & Insel, T. R. (2015). Schizophrenia. *Nature Reviews Disease Primers*, 1(1), 15067. <https://doi.org/10.1038/nrdp.2015.67>
- Kaplan, & Saddock's. (2022). *KAPLAN & SADOCK'S SYNOPSIS OF PSYCHIATRY TWELFTH EDITION* (B. J. R. MD, V. L. M. MD, & MD. Ruiz Pedro, Eds.; 12th ed.). Wolters Kluwer.
- Keefe, R. S. E., & Fenton, W. S. (2007). How Should DSM-V Criteria for Schizophrenia Include Cognitive Impairment? *Schizophrenia Bulletin*, 33(4), 912–920. <https://doi.org/10.1093/schbul/sbm046>
- Kogan, S., Ospina, L. H., & Kimhy, D. (2018). Inflammation in individuals with schizophrenia – Implications for neurocognition and daily function. *Brain, Behavior, and Immunity*, 74, 296–299. <https://doi.org/10.1016/j.bbi.2018.09.016>
- Kroken, R. A., Løberg, E.-M., Drønen, T., Grüner, R., Hugdahl, K., Kompus, K., Skrede, S., & Johnsen, E. (2014). A Critical Review of Pro-Cognitive Drug Targets in Psychosis: Convergence on Myelination and Inflammation. *Frontiers in Psychiatry*, 5. <https://doi.org/10.3389/fpsy.2014.00011>
- Kumar, A., Yadav, M., Parle, M., Dhingra, S., & Dhull, D. K. (2017). Potential drug targets and treatment of schizophrenia. *Inflammopharmacology*, 25(3), 277–292. <https://doi.org/10.1007/s10787-017-0340-5>
- Kusumawardhani AAA, Dharmono S, & Diatri H. (2011). *Konsensus Skizofrenia*. Perhimpunan Dokter Spesialis Kedokteran Jiwa (PDSKJI).

- Lee, E. E., Hong, S., Martin, A. S., Eyler, L. T., & Jeste, D. V. (2017). Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables. *The American Journal of Geriatric Psychiatry*, 25(1), 50–61. <https://doi.org/10.1016/j.jagp.2016.09.009>
- Lejeune, J. A., Northrop, A., & Kurtz, M. M. (2021). A Meta-analysis of Cognitive Remediation for Schizophrenia: Efficacy and the Role of Participant and Treatment Factors. *Schizophrenia Bulletin*, 47(4), 997–1006. <https://doi.org/10.1093/schbul/sbab022>
- Lin, C., Chen, K., Yu, J., Feng, W., Fu, W., Yang, F., Zhang, X., & Chen, D. (2021). Relationship between TNF- $\alpha$  levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients. *BMC Psychiatry*, 21(1), 561. <https://doi.org/10.1186/s12888-021-03569-5>
- Maqbool, M., Dar, A., Gani, I., & Rasool, S. (2019). Risperidone in Schizophrenia: An Overview. *Acta Scientific Pharmaceutical Sciences*, 3(5), 142–147.
- Markiewicz-Gospodarek, A., Markiewicz, R., Borowski, B., Dobrowolska, B., & Łoza, B. (2023). Self-Regulatory Neuronal Mechanisms and Long-Term Challenges in Schizophrenia Treatment. *Brain Sciences*, 13(4), 651. <https://doi.org/10.3390/brainsci13040651>
- Mattila, T., Koeter, M., Wohlfarth, T., Storosum, J., van den Brink, W., de Haan, L., Derks, E., Leufkens, H., & Denys, D. (2015). Impact of DSM-5 Changes on the Diagnosis and Acute Treatment of Schizophrenia. *Schizophrenia Bulletin*, 41(3), 637–643. <https://doi.org/10.1093/schbul/sbu172>
- Momtazmanesh, S., Zare-Shahabadi, A., & Rezaei, N. (2019). Cytokine Alterations in Schizophrenia: An Updated Review. *Frontiers in Psychiatry*, 10. <https://doi.org/10.3389/fpsy.2019.00892>
- Moriarty, O., McGuire, B. E., & Finn, D. P. (2011). The effect of pain on cognitive function: A review of clinical and preclinical research. *Progress in Neurobiology*, 93(3), 385–404. <https://doi.org/10.1016/j.pneurobio.2011.01.002>
- Mosquera, F. E. C., Guevara-Montoya, M. C., Serna-Ramirez, V., & Liscano, Y. (2024). Neuroinflammation and Schizophrenia: New Therapeutic Strategies through Psychobiotics, Nanotechnology, and Artificial Intelligence (AI). *Journal of Personalized Medicine*, 14(4), 391. <https://doi.org/10.3390/jpm14040391>

- Narla, S. T., Lee, Y.-W., Benson, C. A., Sarder, P., Brennand, K. J., Stachowiak, E. K., & Stachowiak, M. K. (2017). Common developmental genome deprogramming in schizophrenia — Role of Integrative Nuclear FGFR1 Signaling (INFS). *Schizophrenia Research*, 185, 17–32. <https://doi.org/10.1016/j.schres.2016.12.012>
- Nuechterlein, K. H., Ventura, J., Subotnik, K. L., Gretchen-Doorly, D., Turner, L. R., Casaus, L. R., Luo, J., Boucher, M. L., Hayata, J. N., Bell, M. D., & Medalia, A. (2022). A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work/school functioning. *Psychological Medicine*, 52(8), 1517–1526. <https://doi.org/10.1017/S0033291720003335>
- Okusaga, O. (2014). Accelerated Aging in Schizophrenia Patients: The Potential Role of Oxidative Stress. *Aging and Disease*, 256–262. <https://doi.org/10.14336/AD.2014.0500256>
- Patlola, S. R., Donohoe, G., & McKernan, D. P. (2023). The relationship between inflammatory biomarkers and cognitive dysfunction in patients with schizophrenia: A systematic review and meta-analysis. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 121, 110668. <https://doi.org/10.1016/j.pnpbp.2022.110668>
- P, P. (2017). “A Review on Biochemical Aspects of Schizophrenia.” *International Journal of Current Research and Review*. <https://doi.org/10.7324/IJCRR.2017.9220>
- Pilowsky M. Paul. (2019). *Serotonin*. Elsevier. <https://doi.org/10.1016/C2013-0-14440-6>
- Puspitosari, W. A., Isnanda, R. G., & Wardaningsih, S. (2023). MENINGKATKAN FUNGSI KOGNITIF ORANG DENGAN SKIZOFRENIA MELALUI REMIDIASI KOGNITIF. *Jurnal Pengabdian Kepada Masyarakat MEMBANGUN NEGERI*, 7(2), 1–13. <https://doi.org/10.35326/pkm.v7i2.868>
- PUTRA, I. P. R. E., & MARIANTO, M. (2023). NEUROBIOLOGI DAN TATALAKSANA GANGGUAN KOGNITIF PADA SKIZOFRENIA. *Jurnal Hasil Penelitian Dan Pengembangan (JHPP)*, 1(3), 161–170. <https://doi.org/10.61116/jhpp.v1i3.155>
- Ramsay, I. S., Nienow, T. M., Marggraf, M. P., & MacDonald, A. W. (2017). Neuroplastic changes in patients with schizophrenia undergoing cognitive remediation: Triple-blind trial. *British Journal of Psychiatry*, 210(3), 216–222. <https://doi.org/10.1192/bjp.bp.115.171496>

- Randa Arung, K., Syamsuddin, S., Teddy Lisal, S., Jaya Ganda, I., Singara, T., & Renaldi, R. (2018). Effect of Non-Computerized Cognitive Remediation on the Cognitive Function of the Schizophrenic Patients Treated with Typical Antipsychotic. *International Journal of Clinical Psychiatry*, 6(2), 27–33. <https://doi.org/10.5923/j.ijcp.20180602.01>
- Reale, M., Costantini, E., & Greig, N. H. (2021). Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment. *Frontiers in Psychiatry*, 12, 536257. <https://doi.org/10.3389/fpsy.2021.536257>
- Réus, G. Z., Fries, G. R., Stertz, L., Badawy, M., Passos, I. C., Barichello, T., Kapczinski, F., & Quevedo, J. (2015). The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. *Neuroscience*, 300, 141–154. <https://doi.org/10.1016/j.neuroscience.2015.05.018>
- Revell, E. R., Neill, J. C., Harte, M., Khan, Z., & Drake, R. J. (2015). A systematic review and meta-analysis of cognitive remediation in early schizophrenia. *Schizophrenia Research*, 168(1–2), 213–222. <https://doi.org/10.1016/j.schres.2015.08.017>
- Saleem, A., Qurat-ul-Ain, & Akhtar, M. F. (2022). Alternative Therapy of Psychosis: Potential Phytochemicals and Drug Targets in the Management of Schizophrenia. *Frontiers in Pharmacology*, 13. <https://doi.org/10.3389/fphar.2022.895668>
- Siti Zahnia, & Dyah Wulan Sumekar. (2016). Kajian epidemiologis skizofrenia. . @inproceedings{Zahnia2016KajianES, Title={Kajian Epidemiologis Skizofrenia}, Author={Siti Zahnia and Dyah Wulan Sumekar}, Year={2016}, Url={https://Api.Semanticscholar.Org/CorpusID:148831794} }, 5, 161–261.
- Sotelo-Ramírez, C. E., Camarena, B., Sanabrais-Jiménez, M., Zaragoza-Hoyos, J. U., Ordoñez-Martínez, B., Escamilla-Orozco, R., & Gómez-González, B. (2023). Toll-Like Receptor (TLR) 1, 2, and 6 Gene Polymorphisms Support Evidence of Innate Immune Factors in Schizophrenia. *Neuropsychiatric Disease and Treatment*, Volume 19, 2353–2361. <https://doi.org/10.2147/NDT.S420952>
- Stahl, M. S. 2013. (2013). *Stahl's Essential Psychopharmacology Neuroscientific Basis and Practical Application Fourth Edition*.
- Stahl, S. M. (2016). *Stahl's Essential Psychopharmacology (N. Muntner (ed.); Fourth Edi)*. Cambridge University Press.

- Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018). Current Concepts and Treatments of Schizophrenia. *Molecules*, 23(8), 2087. <https://doi.org/10.3390/molecules23082087>
- Su, L., Liu, X., Li, Y., Yuan, H., Li, Q., & Li, C. (2023). Comparison of olfactory function, cognitive function and serum tumor necrosis factor- $\alpha$  between bipolar and schizophrenic patients in the remission stage. *BMC Psychiatry*, 23(1). <https://doi.org/10.1186/s12888-023-05330-6>
- Talreja, B., Shah, S., & Kataria, L. (2013). Cognitive function in schizophrenia and its association with socio-demographics factors. *Industrial Psychiatry Journal*, 22(1), 47. <https://doi.org/10.4103/0972-6748.123619>
- Trapp, W., Heid, A., Röder, S., Wimmer, F., & Hajak, G. (2022). Cognitive Remediation in Psychiatric Disorders: State of the Evidence, Future Perspectives, and Some Bold Ideas. In *Brain Sciences* (Vol. 12, Issue 6). MDPI. <https://doi.org/10.3390/brainsci12060683>
- Tripathi, A., Kar, S. K., & Shukla, R. (2018). Cognitive deficits in schizophrenia: Understanding the biological correlates and remediation strategies. In *Clinical Psychopharmacology and Neuroscience* (Vol. 16, Issue 1, pp. 7–17). Korean College of Neuropsychopharmacology. <https://doi.org/10.9758/cpn.2018.16.1.7>
- Vita, A., Barlati, S., Ceraso, A., Nibbio, G., Ariu, C., Deste, G., & Wykes, T. (2021). Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia: A Systematic Review and Meta-analysis of Randomized Clinical Trials. In *JAMA Psychiatry* (Vol. 78, Issue 8, pp. 848–858). American Medical Association. <https://doi.org/10.1001/jamapsychiatry.2021.0620>
- Watkins, C. C., & Andrews, S. R. (2016). Clinical studies of neuroinflammatory mechanisms in schizophrenia. *Schizophrenia Research*, 176(1), 14–22. <https://doi.org/10.1016/j.schres.2015.07.018>
- Wilianto, Y. R., & Yulistiani. (2019). Side Effects of Antipsychotics on Schizophrenia Patients : A Literature Review. *Pharmaceutical Journal of Indonesia*, 2019(2), 35–44
- World Health Organization. (2022). Mental health ATLAS 2022 state profile. Geneva: World Health Organization. (2022). Mental disorders menurut WHO. <https://www.who.int/news-room/fact-sheets/detail/mental-disorders>.
- Wykes, T., Bowie, C. R., & Cella, M. (2024). Thinking About the Future of Cognitive Remediation Therapy Revisited: What Is Left to Solve

Before Patients Have Access? *Schizophrenia Bulletin*, 50(5), 993–1005. <https://doi.org/10.1093/schbul/sbae075>

Zanelli, J., Mollon, J., Sandin, S., Morgan, C., Dazzan, P., Pilecka, I., Reis Marques, T., David, A. S., Morgan, K., Fearon, P., Doody, G. A., Jones, P. B., Murray, R. M., & Reichenberg, A. (2019). Cognitive Change in Schizophrenia and Other Psychoses in the Decade Following the First Episode. *The American Journal of Psychiatry*, 176(10), 811–819. <https://doi.org/10.1176/appi.ajp.2019.18091088>

Zhao, F., Li, B., Yang, W., Ge, T., & Cui, R. (2022). <scp>Brain–immune</scp> interaction mechanisms: Implications for cognitive dysfunction in psychiatric disorders. *Cell Proliferation*, 55(10). <https://doi.org/10.1111/cpr.13295>

Zhou, Y., Li, G., Li, D., Cui, H., & Ning, Y. (2018). Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study. *Journal of Psychopharmacology*, 32(5), 524–532. <https://doi.org/10.1177/0269881118756062>